



**PERSONAL INFORMATION** Carminia Maria Della Corte

 181, Via Nazionale delle Puglie, Pomigliano, Naples, 80038, Italy  
 +39 08119257381  +39 3929160541  
 [carmydellacorte@gmail.com](mailto:carmydellacorte@gmail.com); [carminiamaria.dellacorte@unicampania.it](mailto:carminiamaria.dellacorte@unicampania.it)  
 Facebook: Carminia Della Corte  
 Skype: Carminia Della Corte  
 Sex F | Date of birth 20/02/1987 | Nationality Italian

**EDUCATION AND TRAINING**

February 2020-ongoing Assistant Professor at University of Campania "Luigi Vanvitelli", Department of Precision Medicine, Division of Medical Oncology

January 2018 – December 2019 Postdoctoral fellowship at Thoracic Head and Neck Medical Oncology Department of MD Anderson Cancer Center, Houston, TX, USA. Supervisor: Dr Lauren Byers, MD, MS.

05/07/2012 – 04/07/2017 Residency in Medical Oncology (50/50 cum laude) Second University of Naples – Tutor: Prof. Fortunato Ciardiello  
 Via S. Pansini, 5 - 80131 Naples, Italy  
 +390815666729

Original research thesis in:

***"Role of Hedgehog pathway in the acquisition of resistance to EGFR inhibitors in EGFR mutant non small cell lung cancer models"***

June 2012 Professional Practice Examination  
2<sup>nd</sup> session 2012

Registration to Italian Boards of Medicine for the Province of Naples N° 33709

2006 – 10/10/2011 Degree in Medicine (110/110 cum laude),  
Second University of Naples

Level 7 EQF

Original research thesis (prof. Fortunato Cairdiello) in:

***"Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors"***

Level 4 EQF

2001-2006 Scientific high school degree (100/100)  
High School "E. Torricelli" in Somma Vesuviana (Naples)

**PERSONAL SKILLS**

Mother tongue(s) Italian

Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C1	C1	C1	C1
Spanish	B1	B2	B1	B1	B1
D.E.L.E. Nivel Inicial					

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user  
Common European Framework of Reference for Languages

**Computer skills**

Good knowledge of Microsoft Office 20XX (Word, Excel, Powerpoint) and similar (OpenOffice). Good knowledge of Windows OS (2000, XP, Vista, Seven, 8). Excellent research ability of www contents and use of main navigation browser (IE, Mozilla Firefox, Google Chrome, Opera, Safari), clients e-mail (Microsoft Outlook), software VoIP (Skype) and social network (Facebook and Twitter)

**FURTHER INFORMATIONS****RESEARCH INTERESTS**

Preclinical in vitro and in vivo models of resistance in lung cancer, with particular focus on EGFR mutant lung cancers and small cell lung cancer, and clinical studies of new therapeutics in thoracic tumors.

**TECHNICAL SKILLS AND COMPETENCES**

Cell biology (cell proliferation, survival and apoptosis assays), biochemistry (Western Blot analysis, ELISA assays, PCR), in vivo experiments, sub-investigator in phase I/II and phase III clinical trials.

**CLINICAL TRAINING**

- **MEDICAL ONCOLOGY:** day hospital activities, palliative care, sub-investigator in 25 phase I/II and phase III clinical trials  
University of Campania "Luigi Vanvitelli" -ex Second University in Naples- (2011-present)  
Prof. Fortunato Ciardiello

## SCIENTIFIC ASSOCIATIONS

2012: European Society of Medical Oncology (ESMO)  
 2014: Associazione Italiana Oncologia Toracica (AIOT)  
 2015: American Society of Clinical Oncology (ASCO)  
 2018: American Association for Cancer Research (AACR)  
 2019: International Association for the Study of Lung Cancer (IASLC)

## AWARDS

July 2019: Winner of "FY19 postdoctoral travel award" from Office of postdoctoral affairs and development of MD Anderson Cancer Center, Houston, TX, USA.

October 2019: Winner of "Best poster award" for poster presentation at ESMO annual Congress 2019, Barcellona, Spain.

## OTHER TITLES

April 2018: Diploma of "Pronunciation 2: stress, rythm, and Intonation in American English" at MD Anderson Cancer Center, Houston, TX, USA.

April 2018: Diploma of "Writing and publishing scientific articles" at MD Anderson Cancer Center, Houston, TX, USA.

## PUBLICATIONS

- 
- Morgillo F, Sasso FC, **Della Corte CM**, Vitagliano D, D'Aiuto E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F. *Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines*. Clin Cancer Res. 2013 Jul 1;19(13):3508-19.
  - Morgillo F, Sasso FC, **Della Corte CM**, Festino L, Manzo A, Martinelli E, Troiani T, Capuano A, Ciardiello F. *Metformin in lung cancer: rationale for a combination therapy*. Expert Opin Investig Drugs. 2013 Aug 12.
  - Manzo A, **Della Corte CM**, Festino L, Fasano M, Ciardiello F and Morgillo F. "Management of EGFR-mutated NSCLC patients at progression on first line EGFR-TKIs". Lung Cancer Management. 2014, Vol. 3; 77-84.
  - Fasano M, **Della Corte CM**, Califano R, Capuano A, Troiani T, Martinelli E, Ciardiello F and Morgillo F. "Type III tyrosine kinase inhibitors for the treatment of non-small cell lung cancer". Expert Opin Investig Drugs. 2014
  - Fasano M, **Della Corte CM**, Capuano A, Sasso FC, Papaccio F, Berrino L, Ciardiello F, Morgillo F. "A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial." Clin Lung Cancer. 2015 Jan;16(1):57-9. doi: 10.1016/j.clc.2014.06.010. Epub 2014 Aug 17
  - **Della Corte CM**, Fasano M, Papaccio F, Ciardiello F, Morgillo F. "Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer"

Biomedicines 2014, 2(4), 345-358.

- Iovino F, Orditura M, Auriemma PP, Ciorra FR, Giordano G, Orabona C, Bara F, Sergio R, Savastano B, Fabozzi A, Laterza MM, Ventriglia J, Petrillo A, **Della Corte CM**, DE Vita F. “*Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report.*” *Oncol Lett.* 2015 Mar;9(3):1403-1405.
- Fasano M\*, **Della Corte CM\***, Vicidomini GM, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F and Morgillo F. “*Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: case report and literature review*” *Oncol Lett.* 2015
- Fasano M, **Della Corte CM**, Papaccio F, Ciardiello F, Morgillo F. “*Pulmonary Large Cell Neuroendocrine Carcinoma (LCNEC): from epidemiology to therapy*” *JTO* 2015 Aug;10(8):1133-41.
- **Della Corte CM**, Bellevicine C, Vicidomini G, Vitagliano D, Malapelle U, Accardo M, Fabozzi A, Fiorelli A, Fasano M, Papaccio F, Martinelli E, Troiani T, Troncone G, Santini M, Bianco R, Ciardiello F, Morgillo F. *SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.* *Clin Cancer Res.* 2015 Oct 15;21(20):4686-97.
- **Della Corte CM**, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, Morgillo F. *Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.* *Oncotarget.* 2016 Jan 26;7(4):4265-78.
- Morgillo F, **Della Corte CM**, Fasano M, Ciardiello F. *Mechanisms of resistance to EGFR targeting drugs: Lung Cancer.* *Esmo Open* 2016 May 11;1(3):e000060.
- Troiani T, Napolitano S, **Della Corte CM**, Martini G, Martinelli E, Morgillo F, Ciardiello F. *Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence.* *ESMO Open.* 2016 Sep 16;1(5):e000088.
- **Della Corte CM**, Malapelle U, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, Morgillo F. *Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.* *Oncotarget.* 2017 Apr 4;8(14):23020-23032.
- **Della Corte CM**, Viscardi G, Papaccio F, Esposito G, Martini G, Ciardiello D, Martinelli E, Ciardiello F, Morgillo F. *Implication of the Hedgehog pathway in hepatocellular carcinoma.* *World J Gastroenterol* 2017; 23(24): 4330-4340.
- Morgillo, F., Fasano, M., **Della Corte, C. M.**, Sasso, F. C., Papaccio, F., Viscardi, G., Esposito, G., Di Liello, R., Normanno, N., Capuano, A., Berrino, L., Vicidomini, G., Fiorelli, A., Santini, M., & Ciardiello, F. *Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer.* *ESMO Open*, 2017, 2(2), e000132.
- Giulia Martini, Teresa Troiani, Claudia Cardone, Pietropaolo Vitiello, Vincenzo Sforza,

- Davide Ciardiello, Stefania Napolitano, **Carminia Maria Della Corte**, Floriana Morgillo, Antonio Raucci, Antonio Cuomo, Francesco Selvaggi, Fortunato Ciardiello, Erika Martinelli. *Present and future of metastatic colorectal cancer treatment: A review of new candidate targets*. World J Gastroenterol 2017 July 14; 23(26): 4675-4688
- Stefania Napolitano, Giulia Martini, Erika Martinelli, **Carminia Maria Della Corte**, Floriana Morgillo, Valentina Belli, Claudia Cardone, Nunzia Matrone, Fortunato Ciardiello and Teresa Troiani. *Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells*. Oncotarget 2017.
  - Floriana Morgillo, **Carminia Maria Della Corte**, Anna Diana, Concetta di Mauro, Vincenza Ciaramella, Giusi Barra, Valentina Belli, Elisena Franzese, Roberto Bianco, Evaristo Maiello, Ferdinando De Vita, Fortunato Ciardiello, Michele Orditura. *Phosphatidylinositol 3-kinase (PI3K $\alpha$ )/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells*. Oncotarget 2017.
  - Floriana Morgillo, Giorgio Amendola, **Carminia Maria Della Corte**, Chiara Giacomelli, Lorenzo Botta, Salvatore Di Maro, Anna Messere, Sabrina Taliani, Luciana Marinelli, Maria Letizia Trincavelli, Claudia Martini, Ettore Novellino, Fortunato Ciardiello, Sandro Cosconati. *Dual MET and SMO negative modulators overcome resistance to EGFR inhibitors in human non-small cell lung cancer*. Journal of Medicinal Chemistry 2017.
  - Ronchi A, Cozzolino I, Montella M, Vicidomini G, Morgillo F, **Della Corte CM**, Franco R, Accardo M. *Primary pleural squamous cell carcinoma: A diagnostic challenge*. Cytopathology. 2017
  - **Della Corte CM**, Ciaramella V, Cardone C, La Monica S, Alfieri R, Petronini PG, Malapelle U, Vigliar E, Pepe F, Troncone G, Castellone MD, Troiani T, Martinelli E, Ciardiello F, Morgillo F. *Antitumor efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models*. J Thorac Oncol. 2018
  - Papaccio F\*, **Della Corte CM\***, Viscardi G, Di Liello R, Esposito G, Sparano F, Ciardiello F, Morgillo F. *HGF/MET and the Immune System: Relevance for Cancer Immunotherapy*. Int J Mol Sci. 2018 Nov 14;19(11). pii: E3595. doi: 10.3390/ijms19113595.
  - Diana A, Franzese E, Centonze S, Carlino F, **Della Corte CM**, Ventriglia J, Petrillo A, De Vita F, Alfano R, Ciardiello F, Orditura M. *Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs*. Curr Oncol Rep. 2018 Aug 20;20(10):76. doi: 10.1007/s11912-018-0726-6.
  - Morgillo F, Dallio M, **Della Corte CM**, Gravina AG, Viscardi G, Loguercio C, Ciardiello F, Federico A. *Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota*. Neoplasia. 2018 Jul;20(7):721-733.

- Ciaramella V, **Della Corte CM**, Di Mauro C, Tomassi S, Di Maro S, Troiani T, Martinelli E, Bianco R, Cosconati S, Pierantoni R, Meccariello R, Chianese R, Ciardiello F, Morgillo F. *Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells*. *Oncotarget*. 2018 Apr 10;9(27):19273-19282.
- Ciaramella V, **Della Corte CM**, Ciardiello F, Morgillo F. *Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives*. *Front Endocrinol (Lausanne)*.
- **Della Corte CM**, Viscardi G, Di Liello R, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F. *Role and targeting of anaplastic lymphoma kinase in cancer*. *Mol Cancer*. 2018
- **Della Corte CM**, Gay CM, Byers LA. *Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era*. *Cancer*. 2019 Feb 15;125(4):496-498.
- **Della Corte CM**, Gay CM, Byers LA, Morgillo F. *ILK and SHP2 expression identify a poor prognostic cohort of EGFRmutant lung cancer*. *EBioMedicine*. 2019 Jan;39:5-6
- **Della Corte CM**, Byers LA. *Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRASMutant Lung Cancers*. *Cancer Discov*. 2019 Jan;9(1):16-18.
- Martini G, Cardone C, Vitiello PP, Belli V, Napolitano S, Troiani T, Ciardiello D, **Della Corte CM**, Morgillo F, Matrone N, Sforza V, Papaccio G, Desiderio V, Paul MC, Moreno-Viedma V, Normanno N, Rachiglio AM, Tirino V, Maiello E, Latiano TP, Rizzi D, Signoriello G, Sibilia M, Ciardiello F, Martinelli E. *EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer*. *Mol Cancer Ther*. 2019
- Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, Barra G, Napolitano S, **Della Corte C**, Turano M, Furia M, Troiani T, Morgillo F, De Vita F, Ciardiello F, Martinelli E. *Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines*. *J Exp Clin Cancer Res*. 2019 Jan 28;38(1):41.
- Sen T, Rodriguez BL, Chen L, **Della Corte CM**, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA. *Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer*. *Cancer Discov*. 2019 May;9(5):646-661. doi: 10.1158/2159-8290.CD-18-1020. Epub 2019 Feb 18.
- D'Abrosca B, Ciaramella V, Graziani V, Papaccio F, **Della Corte CM**, Potenza N, Fiorentino A, Ciardiello F, Morgillo F. *Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis*. *Sci Rep*. 2019 Mar 21;9(1):4986.
- Ciaramella V, Sasso FC, Di Liello R, **Della Corte CM**, Barra G, Viscardi G, Esposito G, Sparano F, Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F. *Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC*. *J Exp Clin Cancer Res*. 2019 Apr 26;38(1):178.
- **Della Corte CM**, Barra G, Ciaramella V, Di Liello R, Vicidomini G, Zappavigna S, Luce A,

Abate M, Fiorelli A, Caraglia M, Santini M, Martinelli E, Troiani T, Ciardiello F, Morgillo F. *Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures*. J Exp Clin Cancer Res. 2019 Jun 13;38(1):253. doi: 10.1186/s13046-019-1257-1.

• Sen T, **Della Corte CM**, Milutinovic S, Cardnell RJ, Diao L, Ramkumar K, Gay CM, Stewart CA, Fan Y, Shen L, Hansen RJ, Strouse B, Hedrick MP, Hassig CA, Heymach JV, Wang J, Byers LA. *Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC*. J Thorac Oncol. 2019 Dec;14(12):2152-2163. doi: 10.1016/j.jtho.2019.08.009. Epub 2019 Aug 27.

• Di Liello R, Ciaramella V, Barra G, Venditti M, **Della Corte CM**, Papaccio F, Sparano F, Viscardi G, Iacovino ML, Minucci S, Fasano M, Ciardiello F, Morgillo F. *Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study*. ESMO Open. 2019 Aug 19;4(4):e000536.

• Di Liello R, Sparano F, Iacovino ML, Viscardi G, **Della Corte CM**, Ronchi A, Sabetta RL, Fasano M, Vicidomini G, Reginelli A, Ciardiello F, Morgillo F. *Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma*. Thorac Cancer. 2019 Dec;10(12):2308-2311.

• **Della Corte CM**, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Witsuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. *STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype*. J Thorac Oncol. 2020 Feb 14. pii: S1556-0864(20)30030-7.

• C. Allison Stewart,\*Carl M. Gay,\*Kavya Ramkumar, Kasey R. Cargill,Robert J. Cardnell, Monique B. Nilsson, Simon Heeke, Elizabeth M. Park, Samrat T. Kundu,Lixia Diao, Qi Wang, Li Shen, Yuanxin Xi, **Carminia Maria Della Corte**, Youhong Fan, Kiran Kundu, Curtis R. Pickering, Faye M. Johnson, Jianjun Zhang, Humam Kadara, John D. Minna, Don L. Gibbons, Jing Wang, John V. Heymach, and Lauren Averett Byers. *SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models*. Preprint. PMID: 32577652.

## PRESENTATIONS

- Oral presentation at 55<sup>th</sup> National Conference SIC 2013, Catanzaro, Italy. *Role of Hedgehog pathway in mediating resistance to anti EGFR TKIs in NSCLC*.
- Poster presentation at Annual ESMO 2014 Congress, Madrid, Spain.

*Role of Hedgehog pathway in mediating resistance to EGFR inhibitors in non-small cell lung cancer.*

- Oral presentation at Masterclass in Molecular Oncology conference 2015, Prague, Czech Republic.

*Co-activation of Hedgehog and Met pathways in mediating resistance to gefitinib in non-small cell lung cancer cell line harbouring activating mutation of EGFR.*

- Poster presentation at Annual ESMO 2016 Congress, Copenhagen, Denmark.

*Efficacy of sequential treatment with first, second and third generation EGFR inhibitors and role of Hedgehog pathway in the acquisition of resistance in in vivo NSCLC models.*

- Poster presentation at Annual ESMO 2017 Congress, Madrid, Spain.

*Effect of MEK inhibition on PD-L1 and MCH-1 expression and on cytokines production profile in NSCLC cells and in human lymphocytes.*

- Oral presentation at Clinical trials course 2018, Vienna, Austria.

*Combination of Smo inhibitor and anti-MET antibody in relapsed EGFR mutant NSCLC.*

- Poster presentation at Annual ESMO 2018 Congress, Munich, Germany.

*DNA damaging agents and immunotherapy in NSCLC: is there a STING in the tale?*

- Poster presentation at Annual IASLC Santa Monica Meeting 2019, Los Angeles, USA.

*STING activation is associated with immune checkpoints expression and cisplatin treatment in lung cancer.*

- Poster presentation at Annual ESMO 2019 Congress, Barcelona, Spain.

*Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer.*

- Poster presentation at Annual AACR-EORTC Molecular Targets Meeting 2019, Boston, USA.

*The Aurora kinase A-inhibitor, alisertib, is a potential candidate for combination with immunotherapy in Small Cell Lung Cancer.*

Naples, 09/07/2020